藥事經濟學導論
Introduction to Pharmacoeconomics
學期
108-2
學分
0
學分
當期課號
B282
永久課號
A7249
開課單位
醫務管理研究所
授課教師
黃文鴻、蔡憶文、楊健明
校區
陽明
類別
選修
上課時間表
| 節 | 週二 |
|---|---|
7 15:30–16:20 | 藥事經濟學導論 YN514（陽明） 2 節連堂 |
8 16:30–17:20 |
* 根據陽明交大上課時間表所列
概述
教師未提供此項資料
先修科目
教師未提供此項資料
備註
無備註
教學方式
教師未提供此項資料
評分方式
教師未提供此項資料
課程大綱
教師未提供此項資料
週次計畫
| 週次 | 主題 |
|---|---|
| 第 7 週 | PE and Policy/5. The Demand for Pharmaceuticals (p.145~170) |
| 第 8 週 | PE and Policy/7. Pharmaceutical Prices (p.193~219) PE and Policy/8. Economic Evaluation of New Drugs (p.220~246) |
| 第 9 週 | PE and Policy/9. Pricing Pharmaceuticals in a World Environment (p.247~268) 7. Biosimilar Action Plan: Balancing Innovation and Competition. USFDA, August 2018. 8. Alessandra Ferrario and colleagues. Strategies to achieve fairer prices for generic and biosimilar medicines. BMJ 2020; 368 doi: https://doi.org/10.1136/bmj.l5444 (Published 13 January 2020) |
| 第 10 週 | 9. Joy Li-Yueh Lee, Michael A. Fischer, William H. Shrank, Jennifer M. Polinski, Niteesh K. Choudhry: A systematic review of reference pricing: Implications for US prescription drug spending. The American Journal of Managed Care 2012; 18(11):e430-e437. 10.Olivier J. Wouters, Panos G. Kanavos and Martin McKee. Comparing generic drug markets in Europe and the United States: Prices, volumes, and spending. The Milbank Quarterly 2017, 95(3): 554-601. |
| 第 11 週 | 11.Ravi Gupta, Thomas J Bollyky, Matthew Cohen, Joseph S Ross, Aaron S Kesselheim: Affordability and availability of off-patent drugs in the United States—the case for importing from abroad: observational study. BMJ 2018;360:k831. 12.Comparison of U.S. and International Prices for Top Medicare Part B Drugs by Total Expenditures. DHHS, United States, October 25, 2018. |
| 第 12 週 | 13.全民健康保險藥品給付項目與支付標準 |
| 第 13 週 | 14.Steven G Morgan, Hannah S Bathula and Suerie Moon. Pricing of pharmaceuticals is becoming a major challenge for health systems. BMJ 2020; 368 doi: https://doi.org/10.1136/bmj.l4627 (Published 13 January 2020) 15.Mi Tang, Peipei Song, Jiangjiang He. Progress on drug pricing negotiations in China. BioScience Trends. 2019; 13(6):464-468. |
| 第 14 週 | 16.Market review – European Biosimilar Medicines Market Policy Review. Medicines for Europe 2017. 17.Evelien Moorkens, Arnold G. Vulto, Isabelle Huys, Pieter Dylst, Brian Godman, Simon Keuerleber: Policies for biosimilar uptake in Europe: An overview. PlosOne, December 28, 2017. Available from: https://doi.org/10.1371/journal.pone.0190147 |
| 第 15 週 | PE and Policy/11.Patent Protection (p.303~321) 18.Orphan Drugs in the United States: Providing context and Cost. INQUIVA Institute, October 2017. 19.Orphan Drugs in the United States: Exclusivity, Pricing and Treated Populations. INQUIVA Institute, December 2018. |
| 第 16 週 | 0.台灣生技製藥資本市場分析(黃老師上課講義) 21-1黃文鴻:全民健保對生技製藥產業與民眾用藥的影響,科技報導,2014 年2月號。 21-2黃文鴻: 台灣生技製藥產業與資本市場的「實」與「虛」,工商時報2016/02/25。 21-3黃文鴻: 重新建構製藥產業發展政策與資本市場,工商時報2016/03/16。 21-4 黃文鴻: 愚蠢的生物相似校專利連結,工商時報2019/02/12 21-5 黃文鴻: 正視「生物相似性藥品專利連結」的潛在危機, 自由共和國2019/03/04 |
| 第 17 週 | Final exam |
| 第 18 週 |
教科書
教師未提供此項資料
Office Hours
- 地點
- 教師未提供此項資料
- 時間
- 教師未提供此項資料
- 聯絡方式
- 教師未提供此項資料